Teratogenicity testing in humans: a method demonstrating safety of bendectin

Area of Science:

• Obstetrics and Gynecology
• Teratology
• Pharmacoepidemiology

Background:

• Bendectin was a commonly prescribed medication for nausea and vomiting during pregnancy.
• Concerns were raised regarding its potential teratogenic effects.
• Previous studies yielded conflicting results regarding Bendectin's safety.

Purpose of the Study:

• To investigate the incidence of major birth defects in infants born to women who used Bendectin during pregnancy.
• To compare defect rates in Bendectin-exposed pregnancies with those in the general population.
• To determine if Bendectin is associated with human teratogenicity.

Main Methods:

• A retrospective cohort study was conducted in Leeds and Liverpool.
• Prescription records for Bendectin were collected over 12 and 14 months, respectively.
• Birth notifications were cross-referenced with patient records for 2,298 pregnancies.
• The incidence of major congenital anomalies was compared between exposed and unexposed groups.

Main Results:

• A total of 2,298 births were traced.
• The incidence of major birth defects in infants exposed to Bendectin was compared to relevant population rates.
• No statistically significant increase in major defects was observed in the Bendectin-exposed group.

Conclusions:

• The study found no evidence to suggest that Bendectin is teratogenic in humans.
• The findings support the safety of Bendectin use during pregnancy regarding major congenital anomalies.
• Further research may be warranted to address specific defect types or subpopulations.